Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 16/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11680510 | 0.85 | SIGMAR1 (0.47) | SIGMAR1TBXAS1 | |
| SCHEMBL8216126 | 0.82 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL9092744 | 0.80 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL9882949 | 0.80 | SIGMAR1 (0.51) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL8094515 | 0.80 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL28304994 | 0.79 | TBXAS1 (0.63) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL11229130 | 0.78 | TBXAS1 (0.54) | SIGMAR1TBXAS1 | |
| SCHEMBL1807584 | 0.78 | TBXAS1 (0.54) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL11792681 | 0.78 | TBXAS1 (0.54) | SIGMAR1TBXAS1 | |
| SCHEMBL6996489 | 0.78 | SIGMAR1 (0.54) | SIGMAR1TBXAS1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2013-11-07 | — | — | US | disclosed |
| EP-2642987-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | Faes Farma, S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| EP-2465498-A1 | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions | FAES FARMA, S.A. (ES) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465498-A1 | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions | FAES FARMA, S.A. (ES) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012069442-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069442-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | FAES FARMA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| EP-1042291-B1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1042291-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031064-A1 | ARYL-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296346-A1 | DIPHENYL-AMINE DERIVATIVES: USES, PROCESS OF SYNTHESIS AND PHARMACEUTICAL COMPOSITIONS | CYP2D6, DDC, PAH | SIGMAR1 1329/4885TBXAS1 517/4885TBXA2R 478/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SIGMAR1 4550/4885TBXAS1 3071/4885TBXA2R 2801/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SIGMAR1 4764/4885TBXAS1 1704/4885TBXA2R 1724/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SIGMAR1 4550/4885TBXAS1 3071/4885TBXA2R 2801/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SIGMAR1 4627/4885TBXAS1 2660/4885TBXA2R 2552/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | SIGMAR1 4627/4885TBXAS1 2660/4885TBXA2R 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.